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ABSTRACT 
 
We studied the folding processes of long-sequence hypomurocin peptides and their 
analogs by means of molecular dynamics methods, focusing on the formation of various 
helical structures and intramolecular H-bonds. The evolution of different helical 
conformations, such as the 310-, α- and left-handed α-helices, was examined, taking into 
account the entire sequence and each amino acid of peptides. The results indicated that the 
hypomurocin peptides and their analogs possessed a propensity to adopt helical 
conformations, and they showed a preference for the 310-helical structure over the α-helical 
one. The evolution of a variety of the intramolecular H-bonds, including local and non-local 
interactions, was also investigated. The results pointed out that on the one hand, the 
appearance of local, helix-stabilizing H-bonds correlated with the presence of helical 
conformations, and on the other hand, the non-local H-bonds did not affect significantly the 
formation of helical structures. Additionally, comparing the structural and folding features of 
hypomurocin peptides and their analogs, our study led to the observation that the L-D 
isomerism of isovaline amino acid induced effects on the folding processes of these long-
sequence peptaibol molecules. Accordingly, the hypomurocin peptides and their analogs 
could be characterized by typical structural and folding properties. 
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INTRODUCTION 
 
Hypomurocins are fungal peptides belonging to the peptaibol family,1–3 which show 
antibiotic and hemolytic activities, and they were isolated from the fungus Hypocrea 
muroiana.4 According to their sequence length, two different groups of hypomurocin (HM) 
molecules could be distinguished, such as the short-sequence HM A peptides, as well as the 
long-sequence HM B peptides.4 The former group of hypomurocins includes six peptides 
consisting of 11 amino acid residues, while the latter one comprises also six peptides 
composed of 18 amino acids. The HM molecules contain non-proteinogenic amino acids (i.e. 
α-aminoisobutyric acid, Aib; and isovaline, Iva), and their N-terminal residue is acetylated, 
and furthermore, an amino alcohol (i.e. leucinol, Leuol; and valinol, Valol) is linked at their 
C-terminal end. 
The three-dimensional structure of short-sequence HM A peptides was previously 
investigated by both experimental and theoretical methods. For the HM A-1, HM A-3 and 
HM A-5 molecules, the NMR measurements led to the observation that these peptides 
adopted a mixed helical conformation, containing not only α- and 310-helices, but also type I 
β-turn structure.5,6 In the case of all six HM A peptides, the results derived from our earlier 
theoretical study indicated that these short-sequence peptaibol molecules could be 
characterized by β-turn structures or 310-helical conformation rather than by α-helical 
structure.7 In contrast to the case of HM A peptides, the three-dimensional structure of long-
sequence HM B peptides has not been examined, so far. 
In this theoretical study, the folding processes of six HM B molecules (see Table I) 
were explored in detail, in order to determine their typical structural and folding features. As 
the amino acid sequences represented in Table I indicated, among the HM B peptides, three 
molecules (i.e. HM B-3b, HM B-4 and HM B-5) possess the D-isomer of Iva residue. To 
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investigate the effects of the L-D isomerism of Iva amino acid on the folding processes of 
these long-sequence HM B peptides, the structural and folding properties of the L-Iva-
containing analogs of above-mentioned three molecules were also studied. In the case of these 
analogs, the D-Iva residue was substituted by L-Iva amino acid (see Table I), which is located 
at position 7 of the HM B-3b peptide (i.e. [L-Iva7]HM B-3b), as well as at position 11 of 
the HM B-4 and HM B-5 peptides (i.e. [L-Iva11]HM B-4 and [L-Iva11]HM B-5). 
 
METHODS 
 
Since the HM B peptides and their analogs contain non-proteinogenic amino acids (i.e. 
Aib, D-Iva and L-Iva), as well as amino alcohol residues (i.e. Leuol and Valol), these non-
standard residues were parameterized by means of quantum chemical calculations. In the 
course of parameterization procedure, the second-order Møller-Plesset perturbation method 
and the 6-311G basis set were used. To calculate the partial atomic charges for the non-
proteinogenic amino acids and amino alcohol residues, the restrained electrostatic potential 
(RESP) method was applied. 
For the HM B peptides and their analogs, molecular dynamics (MD) calculations were 
performed, in order to study and identify the structural and folding features of these long-
sequence peptaibol molecules. The MD simulations were carried out with the AMBER 9 
software,8 for which the AMBER 99SB force field9 and the Generalized Born implicit solvent 
model10–12 were applied. The MD calculations were performed at 300 K, using the Langevin 
model to regulate the temperature during the simulations. The time step was set to 2 fs, and 
each bond including hydrogen atom was constrained by the SHAKE algorithm applying a 
tolerance of 10-4 Å. Furthermore, no cutoff was used in the case of non-bonding interactions. 
For each HM B peptide, the MD calculations were started from the same conformation 
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derived from an initial energy-minimization. Afterwards, 100 individual 100-ns-long MD 
simulations with random starting velocities were carried out in the case of all HM B 
molecules, and the MD trajectories were sampled in every ps. 
 
RESULTS AND DISCUSSION 
 
Helicities for Whole Conformation 
 
For the HM B peptides and their analogs, the evolution of different helical structures 
was examined, as follows: i) 310-helix, ii) α-helix and iii) left-handed α-helix. In the case of 
each conformation of peptides, with regard to each snapshot of the MD trajectories, the 
following formula was used to calculate the percentages of various helical contents (i.e. 
helicities, f):13–15 
100⋅=
N
n
f h      (1) 
where nh is the number of amino acid residues satisfying the torsion angle criteria for the 
various helical conformations, which were as follows: i) Φ = -60º ± 30º and Ψ = -30º ± 30º for 
the 310-helix,
16 ii) Φ = -60º ± 30º and Ψ = -50º ± 30º for the α-helix16 and iii) Φ = 60º ± 30º 
and Ψ = 50º ± 30º for the left-handed α-helix.15 The N is the number of all amino acid 
residues found in the sequences of peptides, namely, N = 18 for the HM B peptides and their 
analogs. 
To characterize the helix-forming propensities of peptides, average helicities (fAVE-s) 
were calculated for the ensemble of 100 individual MD calculations, as follows:13–15 
1001 ⋅=
∑
=
M
N
n
f
M
i
hi
AVE     (2) 
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where nhi is the number of amino acid residues located in certain helical region for the ith MD 
trajectory, N is the same as for the previous formula, such as N = 18, and M is the number of 
individual MD simulations, such as M = 100. The fAVE values were calculated for the 310-, α- 
and left-handed α-helices, respectively, and they were labeled as fAVE(310), fAVE(α) and 
fAVE(Lα), respectively. 
The alterations of various average helicities as a function of simulation time in the case 
of HM B peptides and their analogs are shown in Figure 1. Based on the fAVE vs. time plots, it 
could be concluded that the average helicities increased first monotonically, and then they 
fluctuated around their maximum values, taking into account each type of the helical contents. 
As the helicity curves indicated, different final values of fAVE were detected by the end of MD 
simulations, with regard to the various helical contents (see Table II). The helicity curves 
represented in Figure 1, and the values of average helicities shown in Table II pointed out that 
for all peptides, the values of fAVE(310) proved to be larger as compared to those of fAVE(α), and 
nevertheless, the values of fAVE(Lα) were the lowest. These observations revealed that the 
HM B peptides and their analogs could be characterized by 310-helical structure rather than by 
α-helical conformation. 
Based on the average helicities vs. time plots, considering the nature of helicity curves, 
two different groups of HM B molecules could be distinguished. For the first group, including 
the HM B-1, HM B-2 and HM B-3a peptides, as well as the three L-Iva-containing analogs 
(i.e. [L-Iva7]HM B-3b, [L-Iva11]HM B-4 and [L-Iva11]HM B-5), the helicity curves showed 
similar characteristics, taking into account the 310-, α- and left-handed α-helical contents, 
respectively (see Figure 1). For the second group, covering the three HM B peptides 
possessing D-Iva amino acid (i.e. HM B-3b, HM B-4 and HM B-5), the helicity curves were 
found to be also similar, regarding the 310-, α- and left-handed α-helical contents, 
respectively (see Figure 1). However, comparing the above-mentioned two groups of 
Page 6 of 31
John Wiley & Sons, Inc.
Biopolymers: Peptide Science
This article is protected by copyright. All rights reserved.
 7
peptides, the various types of helicity curves showed different characteristics (see Figure 1). 
As the average helicities vs. time plots indicated, the initial slopes of curves were found to be 
larger for the former group of molecules, in comparison with those observed in the case of the 
latter group of molecules. These observations revealed that the HM B-1, HM B-2 and HM B-
3a peptides, as well as the three L-Iva-containing analogs reached their final values of fAVE-s 
sooner than the HM B-3b, HM B-4 and HM B-5 peptides. On the basis of data shown in 
Table II, it could be concluded that for the former molecules, the values of fAVE(310) were 
slightly larger, while the values of fAVE(α) and fAVE(Lα) were slightly lower, as compared to 
those detected in the case of latter molecules. 
 
Helicities for Amino Acid Residues 
 
The 310-, α- and left-handed α-helical contents averaged over the 100 individual MD 
trajectories were calculated not only for the whole conformation, but also for each amino acid 
residue of the HM B peptides and their analogs. The alterations of different average helicities 
per residue as a function of simulation time were illustrated in contour plots (see Figures 2-4), 
which type of representation was earlier used for Lys- and Arg-containing Ala-based 
peptides,13,14 as well as for long-sequence trichobrachin molecules.15 
Based on the contour plots with regard to the 310- and α-helical contents (see Figures 2 
and 3), it could be concluded that the structure of HM B peptides and their analogs can be 
characterized by two helical segments located in the N- and C-terminal parts of molecules, 
respectively. Among them, the N-terminal helical part was found to be longer than the C-
terminal helical part in the case of each HM B peptide (see Figures 2 and 3). The contour 
plots also indicated that the two helical segments were separated by a region possessing lower 
propensity to adopt 310- or α-helical conformation, which was located near the Pro
13 amino 
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acid (see Figures 2 and 3). On the basis of above-mentioned results, it could be proposed that 
the long-sequence HM B peptides showed a tendency to fold into two shorter, separated 
helices rather than a longer, continuous one. Based on the crystal structure of 
alamethicin,
17
 a similar secondary structural motif was observed for this most 
extensively studied, long-sequence peptaibol composed of 20 amino acids.
18,19
 These 
results pointed out that alamethicin could be characterized by mainly α-helical 
structure, which possessed a small distortion generated by the Pro
14
 amino acid. 
Consequently, this peptaibol molecule adopted a conformation, for which the two helical 
segments found in the N- and C-terminal parts of alamethicin, respectively, were linked 
by a bend structure near the Pro residue located at position 14. Similarly to the case of 
alamethicin, this secondary structural motif was also observed in the case of other long-
sequence peptaibol molecules.
1 
Taking into account the contour plots concerning the left-handed α-helical contents (see 
Figure 4), it could be seen that this helical conformation could be detected in the case of Aib 
and Gly amino acids of each HM B molecule, as well as in the case of the D-Iva residues of 
HM B-3b, HM B-4 and HM B-5 peptides. As it was described earlier, the Aib amino acid 
as an achiral residue could adopt both the right-handed and left-handed helical 
conformations.
20
 The analysis of contour plots led to the observation that certain achiral 
amino acids, as well as the D-amino acid residues could be characterized by a larger 
propensity to adopt the left-handed α-helical structure than the other achiral amino 
acids of peptides. These are as follows: i) for the HM B-1 molecule: the Aib7, Aib9, Gly10, 
Aib11, Aib12, Aib15 and Aib16 amino acids; ii) in the case of HM B-2 and HM B-3a peptides: 
the Aib5, Aib7, Aib9, Gly10, Aib11, Aib12, Aib15 and Aib16 amino acids; iii) for the HM B-3b 
molecule: the Aib5, D-Iva7, Aib9, Gly10, Aib11, Aib15 and Aib16 amino acids; iv) in the case of 
HM B-4 and HM B-5 peptides: the Aib5, Aib7, Aib9, D-Iva11, Aib12, Aib15 and Aib16 amino 
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acids; v) for the [L-Iva7]HM B-3b molecule: the Aib5, Aib9, Gly10, Aib11, Aib12, Aib15 and 
Aib16 amino acids; vi) in the case of [L-Iva11]HM B-4 and [L-Iva11]HM B-5 peptides: the 
Aib5, Aib7, Aib9, Gly10, Aib12, Aib15 and Aib16 amino acids. 
 
Intramolecular H-Bonds for Whole Conformation 
 
For the HM B peptides and their analogs, the evolution of different intramolecular H-
bonds formed between the backbone NH donor and CO acceptor groups was investigated. 
Among them, the group of so-called local H-bonds comprises the following helix-stabilizing 
interactions: i) in the case of 310-helix, the i←i+3 (or 1←4) H-bonds evolved between a NH 
group of i+3th and a CO group of ith amino acids; ii) in the case of α- and left-handed α-
helices, the i←i+4 (or 1←5) H-bonds formed between a NH group of i+4th and a CO group 
of ith residues. The other group of intramolecular H-bonds, such as the so-called non-local H-
bonds, includes two types of interactions, as follows: i) the i←i+n H-bonds evolved between 
the backbone CO and NH groups, where n > 4; ii) all types of i→i+n H-bonds formed 
between the backbone NH and CO groups. For all the interactions mentioned afore, an 
intramolecular H-bond was assumed to exist if the N····O distance between the N and O atoms 
of NH and CO groups was within 3.5 Å, and if the N–H····O angle subtended at the H atom by 
the bond to the C atom and the line joining the H and O atoms was larger than 120°. In the 
case of HM B peptides and their analogs, the presence of local and non-local H-bonds was 
studied along the entire sequence of molecules. Based on the 100 individual MD trajectories, 
the average numbers of i←i+3, i←i+4 and non-local H-bonds were calculated, respectively, 
and they were labeled as HB1-4, HB1-5 and HBNL, respectively. 
The alterations of HB1-4 and HB1-5, presented in Figure 5, indicated an increasing 
tendency first, followed by a fluctuation around a certain value for all HM B peptides and 
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their analogs. Based on the Figure 5, it could be seen that in the case of HB1-4 and HB1-5 
curves, also a saturation-like behavior could be found, as it was earlier observed in the case of 
helicity curves. Table III represents the final average numbers of i←i+3 and i←i+4 H-bonds, 
which were detected by the end of MD calculations for each HM B molecule. The HB1-4 and 
HB1-5 curves, as well as the average numbers of local H-bonds pointed out that in the case of 
HM B peptides and their analogs, the amount of i←i+3 H-bonds proved to be larger than the 
amount of i←i+4 H-bonds. This relationship between the two types of local H-bonds 
correlates with the observation made previously for the relationship between the fAVE(310) and 
fAVE(α), namely, the 310-helical content was found to be larger than the α-helical content in the 
case of each HM B molecule. 
Taking into account the nature of HB1-4 and HB1-5 curves, the HM B molecules could be 
divided into two different groups. One of them comprises the HM B-1, HM B-2 and HM B-3a 
peptides, as well as the three L-Iva-containing analogs (i.e. [L-Iva7]HM B-3b, [L-
Iva11]HM B-4 and [L-Iva11]HM B-5), while the other group includes the three HM B peptides 
possessing D-Iva amino acid (i.e. HM B-3b, HM B-4 and HM B-5). Based on Figure 5, it 
could be concluded that the HB1-4 and HB1-5 curves could be characterized by a similar nature 
for the former group of molecules, as well as for the latter group of molecules, respectively. 
Nevertheless, the HB1-4 and HB1-5 curves showed different characteristics, concerning the 
above-mentioned two groups of HM B molecules (see Figure 5). Accordingly, the HB1-4 and 
HB1-5 reached their maximum sooner, as well as the initial slopes of curves were larger for the 
HM B-1, HM B-2 and HM B-3a peptides, as well as for the three L-Iva-containing analogs, 
than for the HM B-3b, HM B-4 and HM B-5 peptides (see Figure 5). These observations are 
in good agreement with the previous findings made in the case of HM B molecules, with 
regard to the helicity curves, taking into account the 310- and α-helical contents. On the basis 
of data presented in Table III, it could be seen that considering the final average numbers of 
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i←i+3 H-bonds, significant differences could not be detected between the afore-mentioned 
two groups of HM B molecules. However, it could be concluded that a larger amount of the 
i←i+4 H-bonds could be observed for the three D-Iva-containing HM B peptides, as 
compared to those found for the HM B-1, HM B-2 and HM B-3a peptides, as well as for the 
three HM B analogs possessing L-Iva amino acid (see Table III). 
The alterations of HBNL as a function of simulation time are shown in Figure 5, while 
the final average numbers of these types of H-bonds are represented in Table III, in the case 
of HM B peptides and their analogs. On the basis of HBNL curves, it could be concluded that 
few non-local H-bonds appeared at an early stage of the MD calculations, however, in the 
majority of cases, their average numbers decreased subsequently by the end of simulation. As 
these HBNL curves revealed, the average numbers of non-local H-bonds decreased as a 
function of simulation time, whereas an increasing tendency could be simultaneously 
detected, concerning the i←i+3 and i←i+4 H-bonds. Among the HM B molecules, for the 
HM B-4 and HM B-5 peptides containing D-Iva amino acid at position 11, different 
characteristics could be observed, namely, the average numbers of non-local H-bonds did not 
show a decreasing tendency during the MD simulations, but they fluctuated around a certain 
value. Based on the HBNL curves (see Figure 5), as well as on data shown in Table III, it could 
be seen that the final average numbers of non-local H-bonds were found to be the lowest by 
the end of simulations, in comparison with those observed for the i←i+3 and i←i+4 H-bonds. 
As it was mentioned previously, on the basis of helicity curves concerning the 310- and 
α-helices, as well as of HB1-4 and HB1-5 curves, two distinct groups of HM B molecules could 
be distinguished. Considering the non-local H-bonds, differences could be also detected 
between the two groups of HM B molecules. As the HBNL curves represented in Figure 5, as 
well as data displayed in Table III pointed out, taking into account the whole simulation time, 
the non-local H-bonds appeared with lower frequency for the HM B-1, HM B-2 and HM B-3a 
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peptides, as well as for the three L-Iva-containing analogs, than in the case of three HM B 
peptides possessing D-Iva amino acid. Based on these results, it could be suggested that the 
non-local H-bonds could presumably produce effects on the formation of helical structures, as 
well as on the folding processes for the latter group of HM B molecules, while these 
intramolecular interactions seemed to not affect the evolution of helical conformations for the 
former group of HM B molecules. 
 
Intramolecular H-Bonds for Amino Acid Residues 
 
As for the average helicities mentioned previously, the alterations of i←i+3 and i←i+4 
H-bonds were examined not only for the whole conformation of HM B molecules, but also for 
all amino acids of peptides. To characterize the H-bond-forming propensities of each amino 
acid residue as an H-bond donor, contour plots were produced in the case of HM B peptides 
and their analogs (see Figures 6 and 7), for which the alterations of average i←i+3 and 
i←i+4 H-bonds per residue were represented as a function of simulation time. 
The analysis of contour plots regarding the i←i+3 H-bonds led to the similar 
observation, as it was made earlier in the case of contour plots concerning the 310-helical 
content. Consequently, for all HM B molecules, two regions displaying larger propensity to 
form i←i+3 H-bonds could be observed, which were located at the N- and C-terminal parts of 
peptides, respectively (see Figure 6). As the contour plots revealed, these two regions were 
separated by the Pro13 amino acid (see Figure 6), which could not form intramolecular H-
bonds as a donor residue. These results also suggested that the structure of long-sequence 
HM B peptides could be characterized by two shorter helices rather than a longer, continuous 
helical conformation. The contour plots with regard to the i←i+3 H-bonds indicated that 
several amino acids showed larger propensity to form i←i+3 H-bonds as a donor residue, as 
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compared to other amino acids of HM B peptides (see Figure 6). They were as follows: i) for 
the HM B-1, HM B-2 and HM B-3a molecules: the Leu4, Aib7, Aib9, Gly10, Aib11, Leu14 and 
Gln17 amino acids; ii) in the case of HM B-3b peptide: the Leu4, Aib11, Leu14 and Gln17 amino 
acids; iii) for the HM B-4 and HM B-5 molecules: the Leu4 Aib7, Aib9, Leu14 and Gln17 amino 
acids; iv) in the case of [L-Iva7]HM B-3b and [L-Iva11]HM B-4 peptides: the Leu4, L-
Iva7/Aib7, Aib9, Gly10, Leu14 and Gln17 amino acids; v) for the [L-Iva11]HM B-5 molecule: the 
Leu4, Aib7, Gly10, Leu14 and Gln17 amino acids. 
Considering the contour plots with regard to the i←i+4 H-bonds, few residues could be 
also detected for all HM B molecules, which possessed larger propensity to participate in the 
i←i+4 H-bonds as a donor, in comparison with other amino acids of peptides (see Figure 7). 
Accordingly, the following residues could be characterized by larger H-bond-forming 
propensity: i) for the HM B-1, HM B-2, HM B-3a, [L-Iva11]HM B-4 and [L-Iva11]HM B-5 
molecules: the Aib5, Aib7, Gly10 and Leuol18/Valol18 residues; ii) in the case of HM B-3b 
peptide: the Aib5, D-Iva7, Val8, Gly10, Aib15 and Valol18 residues; iii) for the HM B-4 and 
HM B-5 molecules: the Aib5, Aib7, Aib9, Gly10, Aib15 and Leuol18/Valol18 residues; iv) in the 
case of [L-Iva7]HM B-3b peptide: the Aib5, Gly10 and Valol18 residues. 
To further characterize the i←i+3 and i←i+4 H-bonds evolved along the entire 
sequence of molecules, another type of graphical representation was applied (see 
Figures 8 and 9). In this case, the presence or absence of various i←i+3 and i←i+4 H-
bonds were represented, as well as the values of final average H-bonds, detected by the 
end of MD simulations, were demonstrated throughout the peptide sequences. For both 
types of H-bonds, the whole range regarding the values of final average H-bonds was 
divided into four equal regions. According to the values of final average H-bonds 
belonging to the different regions, the evolving i←i+3 and i←i+4 H-bonds were 
illustrated by bars with distinct thicknesses (i.e. for lower value, thinner bar; as well as 
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for higher value, thicker bar was used), which connected the residues participating in 
the formation of intramolecular H-bonds. For the absence of i←i+3 and i←i+4 H-bonds, 
a bar was not represented with regard to the two residues. Based on these plots, similar 
observations could be made as for the earlier results, furthermore, differences could be 
also observed between the two groups of HM B molecules mentioned previously, taking 
into account the H-bonding patterns represented in Figures 8 and 9. 
 
CONCLUSIONS 
 
In this study, the evolution of helical structures and intramolecular H-bonds was 
examined for the long-sequence HM B peptides and their analogs. The formation of various 
helical structures was investigated with regard to the entire sequence of molecules, as well as 
to each amino acid of peptides. The results revealed that the HM B peptides and their analogs 
showed a propensity to adopt helical conformations, and nevertheless, these long-sequence 
peptaibol molecules could be characterized by 310-helical structure rather than by α-helical 
structure. The formation and role of different intramolecular H-bonds, including local and 
non-local interactions, were also studied for the HM B peptides and their analogs. The 
presence of i←i+3 and i←i+4 H-bonds correlated with the appearance of helical 
conformations, indicating the relevant helix-stabilizing role of these intramolecular H-bonds. 
On the basis of results concerning the non-local H-bonds, it could be concluded that these 
interactions did not produce significant effects on the formation of helical structures, as well 
as on the folding processes of HM B molecules. In our theoretical study, it was also examined 
how the L-D isomerism of Iva amino acid affected the structural and folding properties of 
long-sequence HM B peptides. Taking into account the evolution of helical structures and 
intramolecular H-bonds, the analysis of results led to the following observations. On the one 
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hand, the L-Iva-containing analogs showed different characteristics as compared to the HM B 
molecules possessing D-Iva residue, and on the other hand, the three analogs could be 
characterized by a similar behavior as observed for the HM B molecules without Iva residue. 
Accordingly, it could be suggested that the L-D isomerism of Iva amino acid could produce 
effects on the folding processes of long-sequence HM B peptides. In summary, a 
comprehensive characterization of the structural properties of HM B peptides and their 
analogs was carried out, and their typical folding features were identified. 
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Table I Amino Acid Sequences of the HM B Peptides and Their Analogs. For the Sequences, Ac is the Acetyl, Aib is the α-
Aminoisobutyric Acid, D-Iva is the D-Isovaline, L-Iva is the L-Isovaline, Valol is the Valinol and Leuol is the Leucinol 
 
Peptides Amino acid sequences 
HM B-1 Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–Aib11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Valol18 
HM B-2 Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–Aib11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Leuol18 
HM B-3a Ac–Aib1–Ala2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–Aib11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Valol18 
HM B-3b Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–D-Iva7–Val8–Aib9–Gly10–Aib11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Valol18 
HM B-4 Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–D-Iva11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Valol18 
HM B-5 Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–D-Iva11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Leuol18 
[L-Iva
7
]HM B-3b Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–L-Iva7–Val8–Aib9–Gly10–Aib11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Valol18 
[L-Iva
11
]HM B-4 Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–L-Iva11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Valol18 
[L-Iva
11
]HM B-5 Ac–Aib1–Ser2–Ala3–Leu4–Aib5–Gln6–Aib7–Val8–Aib9–Gly10–L-Iva11–Aib12–Pro13–Leu14–Aib15–Aib16–Gln17–Leuol18 
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Table II Final Average Helicities (in %) Concerning the 310-, α- and Left-Handed α-Helices for the HM B Peptides and Their Analogs. 
The fAVE(310) Relates to the Average Helicity for the 310-Helix, the fAVE(α) to the Average Helicity for the α-Helix and the fAVE(Lα) to the 
Average Helicity for the Left-Handed α-Helix 
 
Peptides Average helicities 
fAVE(310) fAVE(α) fAVE(Lα) 
HM B-1 55 35 12 
HM B-2 57 36 10 
HM B-3a 57 36 11 
HM B-3b 51 39 17 
HM B-4 53 41 16 
HM B-5 54 42 15 
[L-Iva
7
]HM B-3b 60 36 10 
[L-Iva
11
]HM B-4 58 36 10 
[L-Iva
11
]HM B-5 60 37 9 
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Table III Final Average Numbers of the Various Types of Intramolecular H-Bonds for the HM B Peptides and Their Analogs. The HB1-4 
Relates to the Average Number of i←i+3 H-Bonds, the HB1-5 to the Average Number of i←i+4 H-Bonds and the HBNL to the Average 
Number of Non-Local H-Bonds 
 
Peptides Average numbers of H-bonds 
HB1-4 HB1-5 HBNL 
HM B-1 4.09 0.63 0.39 
HM B-2 4.02 0.59 0.39 
HM B-3a 4.00 0.66 0.35 
HM B-3b 4.26 1.06 0.50 
HM B-4 4.12 1.02 0.68 
HM B-5 4.10 1.07 0.66 
[L-Iva
7
]HM B-3b 4.06 0.51 0.30 
[L-Iva
11
]HM B-4 3.76 0.68 0.32 
[L-Iva
11
]HM B-5 3.93 0.59 0.31 
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FIGURE 1 Alterations of the various average helicities (fAVE-s) as a function of time for (A) 
HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) HM B-4, (F) HM B-5, (G) [L-
Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 peptides. The fAVE(310) relates 
to the 310-helix, the fAVE(α) to the α-helix and the fAVE(Lα) to the left-handed α-helix. 
 
FIGURE 2 Contour plots concerning the alteration of 310-helical content per residue as a 
function of time for (A) HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) HM B-4, (F) 
HM B-5, (G) [L-Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 peptides. 
 
FIGURE 3 Contour plots concerning the alteration of α-helical content per residue as a 
function of time for (A) HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) HM B-4, (F) 
HM B-5, (G) [L-Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 peptides. 
 
FIGURE 4 Contour plots concerning the alteration of left-handed α-helical content per 
residue as a function of time for (A) HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) 
HM B-4, (F) HM B-5, (G) [L-Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 
peptides. 
 
FIGURE 5 Alterations of the average numbers of the various types of intramolecular H-
bonds as a function of time for (A) HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) 
HM B-4, (F) HM B-5, (G) [L-Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 
peptides. The HB1-4 relates to the i←i+3 H-bonds, the HB1-5 to the i←i+4 H-bonds and the 
HBNL to the non-local H-bonds. 
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FIGURE 6 Contour plots regarding the alteration of average i←i+3 H-bonds per residue as a 
function of time for (A) HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) HM B-4, (F) 
HM B-5, (G) [L-Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 peptides. 
 
FIGURE 7 Contour plots regarding the alteration of average i←i+4 H-bonds per residue as a 
function of time for (A) HM B-1, (B) HM B-2, (C) HM B-3a, (D) HM B-3b, (E) HM B-4, (F) 
HM B-5, (G) [L-Iva7]HM B-3b, (H) [L-Iva11]HM B-4 and (I) [L-Iva11]HM B-5 peptides. 
 
FIGURE 8 Presence or absence of the various i←i+3 H-bonds, as well as the values of 
final average H-bonds along the entire sequence for (A) HM B-1, (B) HM B-2, (C) 
HM B-3a, (D) HM B-3b, (E) HM B-4, (F) HM B-5, (G) [L-Iva
7
]HM B-3b, (H) [L-
Iva
11
]HM B-4 and (I) [L-Iva
11
]HM B-5 peptides. The thinner bar relates to the lower 
value, as well as the thicker bar to the higher value of final average H-bonds. 
 
FIGURE 9 Presence or absence of the various i←i+4 H-bonds, as well as the values of 
final average H-bonds along the entire sequence for (A) HM B-1, (B) HM B-2, (C) 
HM B-3a, (D) HM B-3b, (E) HM B-4, (F) HM B-5, (G) [L-Iva
7
]HM B-3b, (H) [L-
Iva
11
]HM B-4 and (I) [L-Iva
11
]HM B-5 peptides. The thinner bar relates to the lower 
value, as well as the thicker bar to the higher value of final average H-bonds. 
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